| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new compounds of formula V-A or their pharmaceutically acceptable salts possessing the properties of PI3-kinase (phosphatidylinositol-3-kinase) activity inhibitors. The compounds can find application for treating diseases and conditions associated with PI3-kinase activity, particularly in a T-cell, B-cell, mastocyte, dendritic cell, or neutrophil. This disease represents one or more diseases specified in cancer, a bone disorder, inflammatory disease, immune disease, respiratory disease or thrombosis. Cancer represents leukaemia or lymphoma, or cancer is specified in acute myeloid leukaemia, chronic lymphocytic leukaemia and multiple myeloma, where lymphoma represents non-Hodgkin lymphoma; an inflammatory or immune disorder is asthma, allergy, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, systemic lupus erythematosus, or graft-versus-host disease. The compound of formula V-A, or its pharmaceutically acceptable salt, or a composition can be used in a combination with rapamycin. In formula V-A:B represents a group of formulawherein Wrepresents phenyl, 6-merous heterocyclyl with one heteroatom specified in oxygen or nitrogen, or C-Ccycloalkyl; q is equal to 0 or 1; Rrepresents hydrogen, C-Calkyl or halogeno; Rrepresents halogeno or C-Calkyl optionally substituted by halogeno; Rrepresents halogeno; Rrepresents hydrogen or C-Calkyl.EFFECT: producing the new compounds for treating the diseases or conditions associated with PI3-kinase activity.62 cl, 19 dwg, 6 tbl, 55 ex |
